公开(公告)号：US20180105574A1

公开(公告)日：2018-04-19

申请号：US15559984

申请日：2016-03-21

Applicant: Universite Paris Descartes ,  Assistance Publique - Hopitaux de Paris ,  Universite Paris - SUD ,  Unviversite Pierre et Marie Curie (Paris 6) ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique (CNRS) ,  Institut Gustave-Roussy

Inventor： Nicolas Dupin ,  Philippe Grange ,  Vincent Calvez ,  Joël Raingeaud

IPC: C07K14/75 ,  A61P29/00 ,  A61P17/10 ,  A61P17/06 ,  C12N7/00 ,  A61K9/00

CPC classification number: C07K14/75 ,  A61K9/0014 ,  A61K9/0019 ,  A61K38/00 ,  A61P17/06 ,  A61P17/10 ,  A61P29/00 ,  C07K2319/00 ,  C12N7/00

Abstract: A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.

公开(公告)号：US09938528B2

公开(公告)日：2018-04-10

申请号：US15534321

申请日：2015-12-10

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Universite Paris-Sud ,  Institut Gustave Roussy ,  Universite Paris Descartes ,  Universite Pierre et Marie Curie (Paris 6) ,  Institut Pasteur ,  Istituto Nazionale per Le Malattie Infettive IRCCS Lazzaro Spallanzani ,  Assistance Publique-Hopitaux de Paris (APHP)

Inventor： Guido Kroemer ,  Jean-Luc Perfettini ,  Marie-Lise Gougeon ,  Awatef Allouch ,  Mauro Piacentini

IPC: C12N15/11 ,  C12N15/113 ,  A61K45/06 ,  A61K31/683 ,  A61K31/5517 ,  A61K31/165 ,  A61K31/395 ,  A61K31/17 ,  A61K31/713 ,  C12Q1/18

CPC classification number: C12N15/113 ,  A61K31/165 ,  A61K31/17 ,  A61K31/395 ,  A61K31/5517 ,  A61K31/683 ,  A61K31/7088 ,  A61K31/713 ,  A61K45/06 ,  C12N15/1132 ,  C12N2310/14 ,  C12N2320/31 ,  C12Q1/18 ,  A61K2300/00

Abstract: The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.

公开(公告)号：US20180057812A1

公开(公告)日：2018-03-01

申请号：US15557646

申请日：2016-03-14

Applicant: NSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS ,  UNIVERSITE PARIS DESCARTES ,  UNIVERSITE PARIS DIDEROT - PARIS 7

Inventor： Carole PEYSSONNAUX ,  Jacques MATHIEU ,  Sara ZUMERLE

IPC: C12N15/113 ,  C07K16/26 ,  C12N15/115

CPC classification number: C12N15/113 ,  A61K9/0031 ,  A61K31/7105 ,  A61K31/713 ,  A61K31/77 ,  C07K16/26 ,  C12N15/115 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14 ,  C12N2310/16 ,  C12N2310/531

Abstract: The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases.

公开(公告)号：US20170342415A1

公开(公告)日：2017-11-30

申请号：US15672384

申请日：2017-08-09

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Universite Paris Descartes

Inventor： Pierre-Louis Tharaux ,  Carole Henique-Greciet

IPC: C12N15/113 ,  G01N33/68 ,  A61K31/7088 ,  C12Q1/68 ,  A61K31/713

CPC classification number: C12N15/113 ,  A61K31/7088 ,  A61K31/713 ,  C12N2310/113 ,  C12Q1/68 ,  C12Q1/6883 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/6893 ,  G01N2800/347

Abstract: The present invention relates to the prevention and the treatment of extracapillary glomerulonephritis such as rapidly progressive glomerulonephritis and collapsing glomerulonephritis.

公开(公告)号：US20170342411A1

公开(公告)日：2017-11-30

申请号：US15534321

申请日：2015-12-10

Applicant: NSERM (Institut National de la Sante et la Recherc Medicale) ,  Universite Paris-Sud ,  Institut Gustave Roussy ,  Universite Paris Descartes ,  Universite Pierre et Marie Curie (Paris 6) ,  Institut Pasteur ,  Istituto Nazionale per Le Malattie Infettive IRCCS Lazzaro Spallanzani ,  Assistance Publique-Hopitaux de Paris (APHP)

Inventor： Guido KROEMER ,  Jean-Luc PERFETTINI ,  Marie-Lise GOUGEON ,  Awatef ALLOUCH ,  Mauro PIACENTINI

IPC: C12N15/113 ,  A61K31/713 ,  A61K31/17 ,  A61K31/395 ,  A61K31/165 ,  A61K31/683 ,  A61K31/5517 ,  C12Q1/18 ,  A61K45/06

CPC classification number: C12N15/113 ,  A61K31/165 ,  A61K31/17 ,  A61K31/395 ,  A61K31/5517 ,  A61K31/683 ,  A61K31/7088 ,  A61K31/713 ,  A61K45/06 ,  C12N15/1132 ,  C12N2310/14 ,  C12N2320/31 ,  C12Q1/18 ,  A61K2300/00

Abstract: The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.

公开(公告)号：US20170340247A1

公开(公告)日：2017-11-30

申请号：US15521075

申请日：2015-10-21

Applicant: Universite Paris Descartes ,  Centre National de la Recherche Scientifique (CNRS)

Inventor： Carolyn Granier-Deferre ,  Anthony James Decasper ,  Elodie Hanrion-Monnier

IPC: A61B5/11 ,  A61B5/16 ,  A61B5/00

CPC classification number: A61B5/1124 ,  A61B3/024 ,  A61B5/162 ,  A61B5/168 ,  A61B5/4082 ,  A61B5/6898 ,  A61B5/742 ,  A61B5/744 ,  A61B5/7475

Abstract: The invention relates to a method of testing an infant, comprising the following steps: displaying a target on a screen; detecting contact made by the infant with the screen inside and/or outside the target; calculating a success parameter on the basis of the contact detected; and recording the calculated success parameter in a memory.

公开(公告)号：US20170253610A1

公开(公告)日：2017-09-07

申请号：US15510427

申请日：2015-09-14

Applicant: Centre National de la Recherche Scientifique (CNRS) ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Universite Paris Descartes ,  Universtie Paris-SUD

Inventor： Maryam Mehrpour ,  Raphael Rodriguez ,  Antje Hienzsch ,  Mai Trang ,  Ahmed Hamai

IPC: C07D493/20 ,  A61K31/366 ,  A61K31/664 ,  A61K31/337 ,  A61K31/704 ,  A61K45/06 ,  A61K31/35

CPC classification number: C07D493/20 ,  A61K31/337 ,  A61K31/35 ,  A61K31/366 ,  A61K31/664 ,  A61K31/704 ,  A61K45/06 ,  C07H7/06 ,  Y02A50/411

Abstract: The present invention concerns compounds of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diasteroisomers thereof formula (I): wherein at least one of W, X and Y is selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR3—(CH2)n—N′R6R7R8; and —O—(CH2)n—N′R6R7R8 and Z is a functional group capable of chelating iron salts. The present invention also concerns the compounds of formula (I) for use as a drug, in particular, in the treatment of cancer and malaria.

公开(公告)号：US20170218467A1

公开(公告)日：2017-08-03

申请号：US15314357

申请日：2015-05-27

Applicant: UNIVERSITE PARIS DESCARTES ,  ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS ,  CHU DE ROUEN ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  UNIVERSITE DE ROUEN ,  UNIVERSITE PARIS DIDEROT

Inventor： Christine ROUZIOUX ,  Jean-Christophe PLANTIER ,  Véronique AVETAND-FENOEL ,  Florence DAMOND ,  Marie GUEDIN ,  Diane DESCAMPS

IPC: C12Q1/70

CPC classification number: C12Q1/703 ,  C12Q1/68 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present invention relates to a method for detecting or quantifying Human Immunodeficiency Virus-2 (HIV-2) nucleic acids in a biological sample, comprising: a) performing a real-time polymerase chain reaction (PCR) or a real-time reverse transcriptase polymerase chain reaction (RT-PCR) on nucleic acids of the biological sample with: (i) at least 4 primers respectively comprising or consisting of: —sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO: 1, a nd—sequence SEQ ID NO: 2 or a sequence having at least 90% identity to SEQ ID NO: 2, a nd—sequence SEQ ID NO: 4 or a sequence having at least 90% identity to SEQ ID NO: 4, a nd—sequence SEQ ID NO: 5 or a sequence having at least 90% identity to SEQ ID NO: 5, a nd (ii) at least 2 labelled probes respectively comprising or consisting of:—sequence SEQ ID NO: 3, a sequence complementary to SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complementary thereof, and—sequence SEQ ID NO: 6, a sequence complementary to SEQ ID NO: 6, or a sequence having at least 90% identity to SEQ ID NO: 6 or the complementary thereof, and b) determining therefrom the presence or absence and/or the quantity of HIV-2 nucleic acids in the biological sample.

公开(公告)号：US20170218057A1

公开(公告)日：2017-08-03

申请号：US15315572

申请日：2015-06-01

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE PARIS DESCARTES

Inventor： Patricia FORGEZ

IPC: C07K16/18 ,  C07K16/26 ,  A61K33/24 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/18 ,  A61K33/24 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/26 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

Abstract: The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.

公开(公告)号：US20170051062A1

公开(公告)日：2017-02-23

申请号：US15119401

申请日：2015-02-18

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Universite Paris Descartes ,  Fondation Imagine ,  Assistance Publique-Hopitaux de Paris (APHP) ,  Centre National de la Recherche Scientifique (CNRS) ,  Universite Grenoble Alpes ,  Commissariat a l'Energie Atomique et aux Energies Alternatives ,  Universite de Bourgogne

Inventor： Zakia Belaid-Choucair ,  Olivier Hermine ,  Carmen Garrido-Fleury ,  Claude Cochet ,  Odile Filhol-Cochet ,  Renaud Seigneuric

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/566 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  C12N15/113

CPC classification number: C07K16/2863 ,  A61K31/4745 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/17 ,  A61K39/39558 ,  A61K45/06 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31 ,  G01N33/566 ,  G01N2333/70503 ,  G01N2333/71 ,  G01N2500/02 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/423 ,  Y02A50/481

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Abstract translation: 本发明涉及用于治疗由NRP-1 / OBR复合物信号传导途径介导的疾病的方法和药物组合物。 特别地，本发明涉及治疗有需要的受试者中选自由癌症，肥胖症和肥胖相关疾病，厌食症，自身免疫性疾病和感染性疾病组成的组的疾病的方法，包括给予受试者治疗有效量 的NRP-1 / OBR信号通路的拮抗剂。